These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30982394)

  • 1. An
    Chung S; Nguyen V; Lin YL; Lafrance-Vanasse J; Scales SJ; Lin K; Deng R; Williams K; Sperinde G; Li JJ; Zheng K; Sukumaran S; Tesar D; Ernst JA; Fischer S; Lazar GA; Prabhu S; Song A
    MAbs; 2019 Jul; 11(5):942-955. PubMed ID: 30982394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a label-free FcRn-mediated transcytosis assay for in vitro characterization of FcRn interactions with therapeutic antibodies and Fc-fusion proteins.
    Chung S; Lin YL; Nguyen V; Kamen L; Zheng K; Vora B; Song A
    J Immunol Methods; 2018 Nov; 462():101-105. PubMed ID: 30030147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.
    Jaramillo CAC; Belli S; Cascais AC; Dudal S; Edelmann MR; Haak M; Brun ME; Otteneder MB; Ullah M; Funk C; Schuler F; Simon S
    MAbs; 2017 Jul; 9(5):781-791. PubMed ID: 28440708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies.
    Bryniarski MA; Tuhin MTH; Acker TM; Wakefield DL; Sethaputra PG; Cook KD; Soto M; Ponce M; Primack R; Jagarapu A; LaGory EL; Conner KP
    J Pharm Sci; 2024 Sep; 113(9):2879-2894. PubMed ID: 38906252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for Functional Characterization of FcRn Interactions with Therapeutic Antibodies and Fc-Fusion Proteins.
    Chung S; Lin YL; Nguyen V; Liu C
    Methods Mol Biol; 2022; 2313():295-303. PubMed ID: 34478146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium.
    Togami K; Wolf W; Olson LC; Card M; Shen L; Schaefer A; Okuda K; Zeitlin L; Pauly M; Whaley K; Pickles RJ; Lai SK
    Front Immunol; 2024; 15():1371156. PubMed ID: 39351230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
    Proetzel G; Roopenian DC
    Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy?
    Bequignon E; Dhommée C; Angely C; Thomas L; Bottier M; Escudier E; Isabey D; Coste A; Louis B; Papon JF; Gouilleux-Gruart V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and applications of AlphaScreen-based FcRn binding assay to characterize monoclonal antibodies.
    Wu Q; Lee HY; Wong PY; Jiang G; Gazzano-Santoro H
    J Immunol Methods; 2015 May; 420():31-7. PubMed ID: 25837414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn.
    Cooper PR; Ciambrone GJ; Kliwinski CM; Maze E; Johnson L; Li Q; Feng Y; Hornby PJ
    Brain Res; 2013 Oct; 1534():13-21. PubMed ID: 23978455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Glycan Moieties in Neonatal Fc Receptor Determine Steady-state Membrane Distribution and Directional Transport of IgG.
    Kuo TT; de Muinck EJ; Claypool SM; Yoshida M; Nagaishi T; Aveson VG; Lencer WI; Blumberg RS
    J Biol Chem; 2009 Mar; 284(13):8292-300. PubMed ID: 19164298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis.
    Hornby PJ; Cooper PR; Kliwinski C; Ragwan E; Mabus JR; Harman B; Thompson S; Kauffman AL; Yan Z; Tam SH; Dorai H; Powers GD; Giles-Komar J
    Pharm Res; 2014 Apr; 31(4):908-22. PubMed ID: 24072267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.
    Gupta S; Gach JS; Becerra JC; Phan TB; Pudney J; Moldoveanu Z; Joseph SB; Landucci G; Supnet MJ; Ping LH; Corti D; Moldt B; Hel Z; Lanzavecchia A; Ruprecht RM; Burton DR; Mestecky J; Anderson DJ; Forthal DN
    PLoS Pathog; 2013; 9(11):e1003776. PubMed ID: 24278022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2017 Jan; 154():39-46. PubMed ID: 27836572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge.
    Stapleton NM; Brinkhaus M; Armour KL; Bentlage AEH; de Taeye SW; Temming AR; Mok JY; Brasser G; Maas M; van Esch WJE; Clark MR; Williamson LM; van der Schoot CE; Vidarsson G
    Sci Rep; 2019 May; 9(1):7363. PubMed ID: 31089170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.